Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2024-03-13 00:00:00 ET · period of report 2024-03-08 · accession 0001628280-24-011026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-03-13 | 2024-03-12+ | BLFS | DuRoss Amy | Dir | S - Sale | $16.92 | -11.2K | 29.4K | -28% | -$189.5K |
| 2024-03-13 | 2024-03-08 | BLFS | DuRoss Amy | Dir | A - Grant | — | +11.3K | 40.6K | +38% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-12 | S | D | 6,135 | $16.86 | 34,508 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.60 to $17.11, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2024-03-08 | A | A | 11,264 | — | 40,643 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. |
| 3 | Common | Common Stock | 2024-03-13 | S | D | 5,065 | $17.00 | 29,443 | D | — | — |